Eris Lifesciences has accepted the resignation of Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The company confirmed the leadership change in a filing with stock exchanges on September 11, 2026.

Vaidyanathan will cease his duties with effect from the close of business hours on September 30, 2026. The Chairman of the board approved the resignation, which Vaidyanathan tendered to pursue professional opportunities outside the organization.

Regulatory Disclosure

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced Para A of Part A of Schedule III and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Milind Talegaonkar, Company Secretary and Compliance Officer, signed the intimation. Eris Lifesciences stated that it places on record its appreciation for Vaidyanathan’s contributions, leadership, and dedication during his tenure.

Eris Lifesciences has entered into a term loan agreement with Axis Bank Limited for ₹45 crore. The company disclosed the transaction on September 9, 2026, stating that the funds are intended to meet other liabilities.

The pharma services firm clarified that this is a routine financial adjustment and will not impact its expected net debt figure at the end of the quarter. The agreement was executed on September 9, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Loan Structure and Security

The total outstanding debt position reflects a mix of term loans and working capital facilities. Eris Lifesciences currently holds a term loan balance of ₹155.77 crore and a working capital loan of ₹55 crore.

Axis Bank will hold a charge on the company’s brands as security for this specific loan facility. There are no related-party transactions involved in this agreement, nor does the bank hold any shareholding in the company.

What the Numbers Show

The disclosure highlights a significant reliance on brand equity as collateral. By securing a charge on its brands for the new ₹45 crore facility, Eris Lifesciences leverages its intangible assets to manage liquidity needs without altering its immediate net debt trajectory. This suggests a strategic approach to maintaining balance sheet flexibility while addressing short-term liability requirements.